Loading news...
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 692 shares of the company's stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $22.07, for a total transaction of $15,272.44. Following the transaction, the insider owned 754,699 shares of the
UNIONDALE, N.Y., Jan. 20, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced that its newly formed subsidiary, ACRES Commercial Realty 2026-FL4 Issuer, LLC (the "Issuer") will issue $879.5 million of non-recourse, floating-rate notes ("Offered Notes," the "Securities" or the "Offering") at a weighted-average cost of the one-month Term Secured Overnight Financing Rate ("SOFR")+168 basis points.
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 5,400 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $24.99, for a total value of $134,946.00. Following the completion of the sale, the insider
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 13,979 shares of the company's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $24.93, for a total transaction of $348,496.47. Following the completion of the sale, the insider directly owned
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low dose gemcitabine (ULDG) as a tumor sensitizer and enrollment completion expected in fourth quarter 2026 Based on preclinical AP3 data showing strong synergy between ACR-368 and anti-PD-L1, company has submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 plus anti-PD-1 therapy in frontline EC subjects; global trial readiness expected mid-2026 Initial data from Phase 1 dose escalation (N=33) for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, showed favorable tolerability; two weekly oral dosing regimens (160 mg QD, 3d on/4d off and 240 mg QD, 2d on/5d off) established with a bi-weekly regimen initiated Tumor shrinkage was observed at ≥120 mg dose level in 9/20 subjects, including a confirmed PR in EC, and unconfirmed PRs in SCLC and sqNSCLC, two tumor types predicted sensitive by AP3, not previously shown sensitive to WEE1 inhibitors in development ACR-6840, a potential first-in-class AP3-derived oral CDK11 inhibitor, nominated as next preclinical development candidate, with IND submission planned for fourth quarter 2026 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 5,000 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $22.41, for a total value of $112,050.00. Following the sale, the insider owned 755,391 shares in the
Shares of ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026.
UNIONDALE, N.Y. , Dec. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.
ACRES Commercial Realty (NYSE: ACR - Get Free Report) and Cherry Hill Mortgage Investment (NYSE: CHMI - Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Volatility and Risk ACRES
ACRES Commercial Realty grew its book value by $1.70 per share sequentially to $29.63 during the third quarter, with the common currently swapping hands at a 20.42% discount. The mREIT bought back 153,000 common shares at a 36% discount to book value during the third quarter, with $2.5 million left on its buyback program. Shareholders in the Series C Preferreds are earning a current yield of 10.15% with these trading at a small 0.8% premium to their liquidation value.
/PRNewswire/ -- ACR Poker's Dual Venom PKO tournaments have wrapped up in spectacular fashion, smashing guarantees once again, and showing why it's one of the
ACRES Commercial Realty Corp. ( ACR ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Kyle K. Brengel Mark Fogel - President, CEO & Director Eldron Blackwell - CFO & Senior VP Andrew Fentress Conference Call Participants Matthew Erdner - JonesTrading Institutional Services, LLC, Research Division Christopher Muller - Citizens JMP Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2025 ACRES Commercial Realty Corp. Earnings Conference Call.
UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $7.5 million of the outstanding shares of both its common and preferred stock.
UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended September 30, 2025.
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. New study results showed that positive Week 12 data across multiple higher-order response measures continue to deepen into Week 28 regardless of prior treatment. These results were then durable for at least three months off drug. Additionally, rosnilimab was well-tolerated with no treatment-related serious adverse events and no malignancies in rosnilimab-treated patients through end-of-trial follow-up (Week 38).
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois.
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on key trial parameters – – All systemic sclerosis patients with sufficient follow-up demonstrated ongoing, transformative clinical responses off all immunomodulators and steroids – – Seven of 8 lupus patients with sufficient follow-up achieved DORIS or renal response; RESET-SLE™ trial expanding to include a no preconditioning cohort with initial clinical data expected in 2026 – – 76 patients enrolled at 77 clinical trial sites globally as of October 24, 2025 – PHILADELPHIA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced positive clinical data and development updates across the RESET-Myositis™, RESET-SSc™ and RESET-SLE trials evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201). These data are being presented in multiple oral and poster presentations at the ongoing American College of Rheumatology (ACR) Convergence 2025, which is being held at the McCormick Place Convention Center in Chicago, Illinois, from October 24-29, 2025.